NRX

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, April 2, 2024
ODD, Research, Growth, Drug discovery, Exercise, NRX, CFO, RNA, Laboratory, Contract research organization, Regenerative medicine, Investigational New Drug, Safety, Spinal cord injury, Intellectual property, Plasma protein binding, Small RNA, FDA, Food, Cryptocurrency

TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023.

Key Points: 
  • TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, today provided a business update and reported financial results for the fourth quarter and financial year ended December 31, 2023.
  • For the fourth quarter of 2023, expenses were US$0.31 million, compared to US$0.39 million in the previous year.
  • For the fourth quarter of 2023, expenses were US$0.40 million, compared to US$0.46 million in the previous year.
  • For the fourth quarter of 2023, expenses were US$0.02 million, compared to US$0.17 million in the previous year.

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

Retrieved on: 
Wednesday, March 27, 2024
Neuroregeneration, Exercise, NRX, Acceleration, Patient, Security (finance)

Following the Acceleration Event, as defined and further detailed in its press release dated September 28, 2023, 9,684,993 warrants were exercised at the cash exercise price of C$0.38, for gross proceeds of C$3,680,297 while the remaining 2,997,347 warrants expired unexercised.

Key Points: 
  • Following the Acceleration Event, as defined and further detailed in its press release dated September 28, 2023, 9,684,993 warrants were exercised at the cash exercise price of C$0.38, for gross proceeds of C$3,680,297 while the remaining 2,997,347 warrants expired unexercised.
  • Furthermore, in addition to the warrants subject to acceleration, the Company garnered gross proceeds of C$276,591 following the exercise of warrants not under acceleration from two distinct groups:
    556,818 warrants stemming from a private placement that concluded in September 2023, with an exercise price of C$0.34; and
    181,818 warrants from another private placement that also wrapped up in September 2023, featuring an exercise price of C$0.48.
  • "We are pleased to note the exercise of both accelerated and non-accelerated warrants, resulting in gross proceeds of approximately C$4 million for the Company."
  • "The new funds received, will boost NurExone’s development and commercial efforts, including the engaging of biopharma collaborators for new indications.

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

Retrieved on: 
Friday, March 22, 2024
Drug discovery, Rat, NRX, PTEN, Patient, Contract research organization, IND, Regenerative medicine, Behavior, Spinal cord, Spinal cord injury, SCI, Pharmaceutical industry

This large-scale animal testing represents a significant step towards filing an Investigational New Drug (IND) application in the US for NurExone’s ExoPTEN therapy for spinal cord injury (SCI).

Key Points: 
  • This large-scale animal testing represents a significant step towards filing an Investigational New Drug (IND) application in the US for NurExone’s ExoPTEN therapy for spinal cord injury (SCI).
  • Under the terms of the agreement, Vivox will provide Contract Research Organization (CRO) services to NurExone, as a prerequisite to commencing Human Trials under the planned IND.
  • The testing will encompass mobility, behavior, motor and sensory recovery of rats following Spinal Cord Injury and treatment with ExoPTEN," said Dr. Lior Shaltiel, CEO of NurExone.
  • By collaborating with Vivox, NurExone aims to accelerate the development and regulatory path of ExoPTEN, to bring this potentially transformative treatment to patients in need.

NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

Retrieved on: 
Friday, March 15, 2024
OTC Markets Group, TSX Venture Exchange, FICC, NRX, Environment, DTC, Regenerative medicine, Depository Trust Company, OTCQB, Security (finance)

Listing on the OTCQB is subject to approval of the OTC Markets Group.

Key Points: 
  • Listing on the OTCQB is subject to approval of the OTC Markets Group.
  • Mr. Yoram Drucker, chairman of NurExone’s board, commented, "Expanding our presence to the OTCQB underscores our commitment to enhancing investor engagement and liquidity for our shareholders.
  • OTCQB listing will offer US investors an easy way to invest in NurExone.
  • The Company remains dedicated to keeping shareholders informed throughout the application process.

NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

Retrieved on: 
Friday, March 8, 2024
NRX, Science, Exosome, Laboratory, Research, Partnership, Renewable energy

The Technion’s commitment to science research and biotech innovation are reflected in the decision to allocate a new facility on the university’s campus to the Company.

Key Points: 
  • The Technion’s commitment to science research and biotech innovation are reflected in the decision to allocate a new facility on the university’s campus to the Company.
  • This exclusive location will provide NurExone with ongoing access to top talent, resources and human capital from the university.
  • The new facilities will play a pivotal role in driving the development of the Company’s revolutionary ExoPTEN and ExoTherapy platform, positioning NurExone at the forefront of exosome-based therapies advancements.
  • Dr. Noa Avni, Director of R&D at NurExone, states, "We're pleased to be expanding to a cutting-edge research and development facility on the Technion campus, tailored to our present and future needs for the ExoTherapy platform and ExoPTEN development.

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

Retrieved on: 
Friday, March 1, 2024
EVS, Therapy, Aegle, Harvard Medical School, Exosome, NRX, AbbVie, Quality, University, Conference, Patient, Development, Seminal vesicles, CMC, Medical device

Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."

Key Points: 
  • Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."
  • Dr. Sarel joins a prestigious lineup of speakers including representatives from leading exosome companies, e.g.
  • The summit will take place on April 23-25, 2024 in Boston, MA.
  • To learn more about the summit and to register, please visit the Conference Website .

NurExone’s Intellectual Property Portfolio Expands

Retrieved on: 
Tuesday, February 20, 2024
EVS, EV, Exosome, 3D, NRX, PCT, Cell, B cell, RNA, Patent, 3D bioprinting, IP, Intellectual property, Seminal vesicles, Fine chemical

TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies.

Key Points: 
  • TORONTO and HAIFA, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, proudly underscores its expanding Intellectual Property (IP) portfolio, which will serve as the foundation for its strategic goal of licensing the innovative ExoTherapy platform to interested biotech companies.
  • NurExone’s Intellectual property portfolio describes the ExoTherapy platform’s comprehensive technology and processes for the production of nanodrugs including large scale production of exosomes, loading of active molecules and the composition of the exosomes themselves.
  • The loading technology was presented to the public in the press release of February 12, 2024.
  • Aspects of the company’s platform which relate to Extracellular Vesicles (EVs) production are described in a growing intellectual property portfolio with two PCT applications currently in National Phases.

NurExone Launches Licensing Efforts for ExoTherapy Platform

Retrieved on: 
Wednesday, February 14, 2024
EVS, Messenger, Plasma protein binding, Exosome, NRX, PCT, Cell, Seminal vesicles, RNA, Patent, Patient, Listeria monocytogenes non-coding RNA, MicroRNA, Carbohydrate, Small RNA, Tissue, Environment, Fine chemical

TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.

Key Points: 
  • TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
  • The Company’s ExoTherapy platform for exosome-based therapy production includes: (i) large-scale exosome production using the Company’s dedicated bioreactor, (ii) synthesis of therapeutic cargo and (iii) processes to load the therapeutic cargo, creating nanodrugs.
  • Dr. Lior Shaltiel, CEO of NurExone, commented, “Exosomes have the potential to be the ultimate drug delivery system.
  • ExoPTEN, for patients with acute spinal cord injuries, is being developed on our platform, and we expect great success through licensing our technology for other indications!”.

Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant

Retrieved on: 
Friday, February 2, 2024
NRX, CMC, European, Orphan drug, Patient, FDA, EMA, Orphan, Food, European Medicines Agency, Pharmaceutical industry

This strategic move follows the recent grant of Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”) for ExoPTEN.

Key Points: 
  • This strategic move follows the recent grant of Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”) for ExoPTEN.
  • Dr. Ina Sarel, Head of CMC, Quality, and Regulation at NurExone Biologic, expressed enthusiasm about the development, stating, "Embarking on the European Orphan Drug Designation process marks a crucial milestone in our mission to bring life-changing treatments to patients in need around the world."
  • The initiation of the European Orphan Drug Designation process represents a strategic move to broaden the reach of this promising treatment globally.
  • To expedite the application process, the Company has enlisted the expertise of an external consultant to secure European Orphan Drug Designation.

NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market

Retrieved on: 
Wednesday, January 17, 2024
Spinal cord injury, Agreement, Patient, Advertising, Exosome, Administration, NRX, SCI, TSX Venture Exchange, Pharmaceutical industry

The collaborative agreement between NurExone and Inteligex Inc. (“Inteligex”), announced in October 2023, to expand the Company’s portfolio, is now officially underway.

Key Points: 
  • The collaborative agreement between NurExone and Inteligex Inc. (“Inteligex”), announced in October 2023, to expand the Company’s portfolio, is now officially underway.
  • As part of this collaboration, we will use our platform to produce and load exosomes from Inteligex’s cell line to deliver combination regenerative therapy for Spinal Cord Injury (SCI) patients.
  • This win-win collaboration will expand our potential markets and is in line with our belief of patient, first.”
    Dr. Paul Bradshaw, CEO of Inteligex, stated that “Spinal cord injury is the single most expensive healthcare condition in the world.
  • The Agreement is effective for four months from the effective date and the total consideration payable to BullVestor is CAD$300,000 on the effective date.